Prasugrel Single Antiplatelet Therapy versus Aspirin and Clopidogrel Dual Antiplatelet Therapy for Flow Diverter Treatment for Cerebral Aneurysms: A Retrospective Multicenter Study

References

1. 1.↵
   1. Fiehler J,
   2. Ries T

   . Prevention and treatment of thromboembolism during endovascular aneurysm therapy. Klin Neuroradiol 2009;19:73–81 doi:10.1007/s00062-009-8029-9 pmid:19636680

   CrossRefPubMed
2. 2.↵
   1. Zhou G,
   2. Su M,
   3. Yin YL, et al

   . Complications associated with the use of flow-diverting devices for cerebral aneurysms: a systematic review and meta-analysis. Neurosurg Focus 2017;42:E17 doi:10.3171/2017.3.FOCUS16450 pmid:28565981

   CrossRefPubMed
3. 3.↵
   1. Al-Mufti F,
   2. Cohen ER,
   3. Amuluru K, et al

   . Bailout strategies and complications associated with the use of flow-diverting stents for treating intracranial aneurysms. Interv Neurol 2020;8:38–54 doi:10.1159/000489016 pmid:32231694

   CrossRefPubMed
4. 4.↵
   1. Tonetti DA,
   2. Jankowitz BT,
   3. Gross BA

   . Antiplatelet therapy in flow diversion. Neurosurgery 2020;86:S47–52 doi:10.1093/neuros/nyz391 pmid:31838537

   CrossRefPubMed
5. 5.↵
   1. Lobsien D,
   2. Clajus C,
   3. Behme D, et al

   . Aneurysm treatment in acute SAH with hydrophilic-coated flow diverters under single-antiplatelet therapy: a 3-center experience. AJNR Am J Neuroradiol 2021;42:508–15 doi:10.3174/ajnr.A6942 pmid:33446495

   Abstract/FREE Full Text
6. 6.↵
   1. Hellstern V,
   2. Aguilar Perez M,
   3. Henkes E, et al

   . Use of a p64 MW flow diverter with hydrophilic polymer coating (HPC) and prasugrel single antiplatelet therapy for the treatment of unruptured anterior circulation aneurysms: safety data and short-term occlusion rates. Cardiovasc Intervent Radiol 2022;45:1364–74 doi:10.1007/s00270-022-03153-8 pmid:35562486

   CrossRefPubMed
7. 7.↵
   1. Bhogal P,
   2. Petrov A,
   3. Rentsenkhu G, et al

   . Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment. Interv Neuroradiol 2022;28:266–76 doi:10.1177/15910199211029503 pmid:34233547

   CrossRefPubMed
8. 8.↵
   1. de Castro-Afonso LH,
   2. Nakiri GS,
   3. Abud TG, et al

   . Treatment of distal unruptured intracranial aneurysms using a surface-modified flow diverter under prasugrel monotherapy: a pilot safety trial. J Neurointerv Surg 2021;13:647–51 doi:10.1136/neurintsurg-2020-017262 pmid:33632882

   Abstract/FREE Full Text
9. 9.↵
   1. Fifi JT,
   2. Brockington C,
   3. Narang J, et al

   . Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013;34:716–20 doi:10.3174/ajnr.A3405 pmid:23194833

   Abstract/FREE Full Text
10. 10.↵
    1. Warlo EM,
    2. Arnesen H,
    3. Seljeflot I

    . A brief review on resistance to P2Y(12) receptor antagonism in coronary artery disease. Thromb J 2019;17:11 doi:10.1186/s12959-019-0197-5 pmid:31198410

    CrossRefPubMed
11. 11.↵
    1. Pearce S,
    2. Maingard JT,
    3. Kuan Kok H, et al

    . Antiplatelet drugs for neurointerventions, Part 2: clinical applications. Clin Neuroradiol 2021;31:545–58 doi:10.1007/s00062-021-00997-4 pmid:33646319

    CrossRefPubMed
12. 12.↵
    1. Pearce S,
    2. Maingard JT,
    3. Li K, et al

    . Antiplatelet drugs for neurointerventions, Part 1: clinical pharmacology. Clin Neuroradiol 2020;30:425–33 doi:10.1007/s00062-020-00910-5 pmid:32424668

    CrossRefPubMed
13. 13.↵
    1. Jesser J,
    2. Alberalar ND,
    3. Kizilkilic O, et al

    . Safety and efficacy of the FRED Jr flow re-direction endoluminal device for intracranial aneurysms: retrospective multicenter experience with emphasis on midterm results. Front Neurol 2021;12:722183 doi:10.3389/fneur.2021.722183 pmid:34659086

    CrossRefPubMed
14. 14.↵
    1. Vollherbst DF,
    2. Lucking H,
    3. DuPlessis J, et al

    . The FRESH study: treatment of intracranial aneurysms with the new FRED X flow diverter with antithrombotic surface treatment technology: first multicenter experience in 161 patients. AJNR Am J Neuroradiol 2023;44:474–80 doi:10.3174/ajnr.A7834 pmid:36997283

    Abstract/FREE Full Text
15. 15.↵
    1. Vollherbst DF,
    2. Cekirge HS,
    3. Saatci I, et al

    . First clinical multicenter experience with the new Pipeline Vantage flow diverter. J Neurointerv Surg 2023;15:63–69 doi:10.1136/neurintsurg-2021-018480 pmid:35172983

    Abstract/FREE Full Text
16. 16.↵
    1. Mohlenbruch MA,
    2. Seker F,
    3. Ozluk E, et al

    . Treatment of ruptured blister-like aneurysms with the FRED flow diverter: a multicenter experience. AJNR Am J Neuroradiol 2020;41:2280–84 doi:10.3174/ajnr.A6849 pmid:33122212

    Abstract/FREE Full Text
17. 17.↵
    1. O’Kelly CJ,
    2. Krings T,
    3. Fiorella D, et al

    . A novel grading scale for the angiographic assessment of intracranial aneurysms treated using flow diverting stents. Interv Neuroradiol 2010;16:133–37 doi:10.1177/159101991001600204 pmid:20642887

    CrossRefPubMed
18. 18.↵
    1. Roy D,
    2. Milot G,
    3. Raymond J

    . Endovascular treatment of unruptured aneurysms. Stroke 2001;32:1998–2004 doi:10.1161/hs0901.095600 pmid:11546888

    Abstract/FREE Full Text
19. 19.↵
    1. Schror K

    . Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349–56 doi:10.1055/s-2007-996108

    CrossRefPubMed
20. 20.↵
    1. Ferreira M,
    2. Freitas-Silva M,
    3. Assis J, et al

    . The emergent phenomenon of aspirin resistance: insights from genetic association studies. Pharmacogenomics 2020;21:125–40 doi:10.2217/pgs-2019-0133 pmid:31957546

    CrossRefPubMed
21. 21.↵
    1. Borchert RJ,
    2. Simonato D,
    3. Hickman CR, et al

    . P2Y12 inhibitors for the neurointerventionalist. Interv Neuroradiol 2022;28:92–103 doi:10.1177/15910199211015042 pmid:33947251

    CrossRefPubMed
22. 22.↵
    1. Stetler WR,
    2. Chaudhary N,
    3. Thompson BG, et al

    . Prasugrel is effective and safe for neurointerventional procedures. J Neurointerv Surg 2013;5:332–36 doi:10.1136/neurintsurg-2012-010302 pmid:22619468

    Abstract/FREE Full Text
23. 23.↵
    1. Atallah E,
    2. Saad H,
    3. Bekelis K, et al

    . The use of alternatives to clopidogrel in flow-diversion treatment with the Pipeline Embolization Device. J Neurosurg 2018;129:1130–35 doi:10.3171/2017.5.JNS162663 pmid:29219758

    CrossRefPubMed
24. 24.↵
    1. Podlasek A,
    2. Al Sultan AA,
    3. Assis Z, et al

    . Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis. J Neurointerv Surg 2020;12:148–55 doi:10.1136/neurintsurg-2019-014996 pmid:31273075

    Abstract/FREE Full Text
25. 25.↵
    1. Xia P,
    2. He C,
    3. Chen L, et al

    . Efficacy and safety of prasugrel therapy for intracranial aneurysms with endovascular treatment: a meta-analysis. J Neurol Sci 2019;397:174–78 doi:10.1016/j.jns.2019.01.005 pmid:30641247

    CrossRefPubMed
26. 26.↵
    1. Cagnazzo F,
    2. Perrini P,
    3. Lefevre PH, et al

    . Comparison of prasugrel and clopidogrel used as antiplatelet medication for endovascular treatment of unruptured intracranial aneurysms: a meta- analysis. AJNR Am J Neuroradiol 2019;40:681–86 doi:10.3174/ajnr.A6004 pmid:30872419

    Abstract/FREE Full Text
27. 27.↵
    1. Hohenstatt S,
    2. Ulfert C,
    3. Herweh C, et al

    . Acute intraprocedural thrombosis after flow diverter stent implantation: risk factors and relevance of standard observation time for early detection and management. Clin Neuroradiol 2022;33:343–51 doi:10.1007/s00062-022-01214-6 pmid:36068407

    CrossRefPubMed
28. 28.↵
    1. Mohammaden MH,
    2. English SW,
    3. Stapleton CJ, et al

    . Safety and efficacy of ticagrelor as single antiplatelet therapy in prevention of thromboembolic complications associated with the Pipeline Embolization Device (PED): multicenter experience. J Neurointerv Surg 2020;12:1113–16 doi:10.1136/neurintsurg-2020-015978 pmid:32471826

    Abstract/FREE Full Text
29. 29.↵
    1. de Castro-Afonso LH,
    2. Nakiri GS,
    3. Abud TG, et al

    . Aspirin monotherapy in the treatment of distal intracranial aneurysms with a surface modified flow diverter: a pilot study. J Neurointerv Surg 2021;13:336–41 doi:10.1136/neurintsurg-2020-017024 pmid:33514613

    Abstract/FREE Full Text
30. 30.↵
    1. Cagnazzo F,
    2. Perrini P,
    3. Dargazanli C, et al

    . Treatment of unruptured distal anterior circulation aneurysms with flow-diverter stents: a meta-analysis. AJNR Am J Neuroradiol 2019;40:687–93 doi:10.3174/ajnr.A6002 pmid:30872418

    Abstract/FREE Full Text
31. 31.↵
    1. Brinjikji W,
    2. Lanzino G,
    3. Cloft HJ, et al

    . Risk factors for ischemic complications following Pipeline Embolization Device treatment of intracranial aneurysms: results from the IntrePED Study. AJNR Am J Neuroradiol 2016;37:1673–78 doi:10.3174/ajnr.A4807 pmid:27102308

    Abstract/FREE Full Text
32. 32.↵
    1. Mahoney EM,
    2. Wang K,
    3. Arnold SV, et al

    . Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010;121:71–79 doi:10.1161/CIRCULATIONAHA.109.900704 pmid:20026770

    Abstract/FREE Full Text
33. 33.↵
    1. Kim K,
    2. Lee TA,
    3. Touchette DR, et al

    . Comparison of 6-month costs between oral antiplatelet agents following acute coronary syndrome. J Manag Care Spec Pharm 2018;24:800–12 doi:10.18553/jmcp.2018.24.8.800 pmid:30058986

    CrossRefPubMed